Browsing Tag
Incyte Biosciences Japan
1 post
Japan approves Minjuvi for relapsed follicular lymphoma: What does this dual-CD immunotherapy mean for the market?
Incyte’s Minjuvi gets Japan approval for relapsed FL. Find out how this dual-CD regimen is reshaping immunotherapy options in a high-need market.